We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd
News

Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd

Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd
News

Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Serologicals Corporation has announced completed its previously announced acquisition of Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc.

Based in Cambridge, U.K., Cytomyx Ltd. is a provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell lines commercially
available, and more in its pipeline, Cytomyx Ltd. offers a large portfolio of distinct ion channel cell lines.

Serologicals paid U.S. $7 million for the stock of Cytomyx Ltd.

“We are very pleased to announce the completion of the Cytomyx Ltd. acquisition,” said David A. Dodd, President and CEO of Serologicals. “Ion channels represent the third largest target class for Biopharma research and drug development today. The expertise that Cytomyx Ltd. brings will greatly enhance our drug discovery products and services portfolio with therapeutically relevant ion channel cell lines and ion channel screening services. With GPCRs, kinases, and ion channels, Serologicals will better serve the needs of our Biopharma customers through a comprehensive portfolio offering.”

Advertisement